Trials / Completed
CompletedNCT00368979
Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects
Clinical Evaluation of Dutasteride in Benign Prostatic Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparative Study of GI198745 (Dutasteride) in Subjects With Benign Prostatic Hyperplasia.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 378 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of GI198745 0.5mg given once daily for 52 weeks to Benign Prostatic Hyperplasia (BPH) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dutasteride | once daily |
| DRUG | Placebo | once daily |
Timeline
- Start date
- 2006-02-17
- Primary completion
- 2007-12-01
- Completion
- 2007-12-06
- First posted
- 2006-08-29
- Last updated
- 2018-09-26
- Results posted
- 2009-04-02
Locations
26 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00368979. Inclusion in this directory is not an endorsement.